Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

0.4787 -0.0213 (-4.26%)
Streaming Delayed Price Updated: 2:15 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Top movers in Tuesday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Most active stocks in Tuesday's session
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session. 
Via Chartmill
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
What's going on in today's session
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Gapping stocks in Tuesday's session
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments. 
Via Benzinga
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
From Rallybio Corporation
Via Business Wire
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Which stocks have an unusual volume on Monday?
Unusual volume stocks are being observed in Monday's session. 
Via Chartmill
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential. 
Via Benzinga
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
From Rallybio Corporation
Via Business Wire
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
From Rallybio Corporation
Via Business Wire
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
From Rallybio Corporation
Via Business Wire
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.